tiprankstipranks
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE

Ultragenyx Pharmaceutical (RARE) Cash flow

570 Followers

Ultragenyx Pharmaceutical Cash Flow

RARE's free cash flow for Q3 2023 was $―. For the 2023 fiscal year, RARE's free cash flow was decreased by $-114.80M and operating cash flow was $-117.87M. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Operating Cash Flow
$ -481.24M$ -380.46M$ -338.69M$ -132.22M$ -345.38M$ -290.57M
Investing Cash Flow
$ 103.42M$ -291.65M$ -195.37M$ -179.12M$ -13.04M$ -33.33M
Financing Cash Flow
$ 59.41M$ 501.21M$ 118.51M$ 600.27M$ 679.31M$ 336.85M
Cash Flow From Discontinued Operation
------
Other Cash Adjustment Inside Changein Cash
------
End Cash Position
$ 407.36M$ 137.60M$ 309.54M$ 726.29M$ 436.24M$ 115.53M
Income Tax Paid Supplemental Data
------
Interest Paid Supplemental Data
------
Issuance Of Capital Stock
---$ 511.21M$ 355.24M$ 309.02M
Issuance Of Debt
------
Repayment Of Debt
----$ 0.00$ 0.00
Free Cash Flow
$ -431.81M$ -526.59M$ -411.79M$ -176.13M$ -370.21M$ -294.64M
Domestic Sales
------
Foreign Sales
------
Currency in USD

Ultragenyx Pharmaceutical Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis